Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Endocrine therapy resistance in ER+ metastatic breast cancer

Nikhil Wagle • 19 Apr 2021
AACR 2021
Breast Cancer

Nikhil Wagle, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of resistance to endocrine therapies and CDK4/6 inhibitors in estrogen receptor-positive (ER+) metastatic breast cancer. Dr Wagle outlines work investigating mechanisms of resistance. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Nikhil Wagle, MD, has participated in a consultancy/advisory role for Eli Lilly, has received grant support from Puma Biotechnologies, and has participated in a scientific advisory board for and is a stockholder of Relay Therapeutics.

More from Nikhil Wagle

1:27
Treating ER+ breast cancer patients with endocrine therapy resistance
Nikhil Wagle • 19 Apr 2021
5:32
The metastatic breast cancer project: accelerating genomics research
Nikhil Wagle • 3 Jun 2016

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals